

EDO Principal Correspondence Control

FROM: DUE: / /

EDO CONTROL: G20010076
DOC DT: 02/08/01
FINAL REPLY:

Carl L. Tommaso
The Society for Cardiac
Angiography and Interventions

TO:

Chairman Meserve

FOR SIGNATURE OF : ** GRN **

CRC NO: 01-0107

DESC:

Request the Appointment of an Interventional
Cardiologist to the Advisory Committee on the
Medical Uses of Isotopes

ROUTING:

Travers
Paperiello
Miraglia
Norry
Reiter
Craig
Burns/Cyr

DATE: 02/14/01

ASSIGNED TO: CONTACT:

NMSS

Kane

SPECIAL INSTRUCTIONS OR REMARKS:

For Appropriate Action.

OFFICE OF THE SECRETARY
CORRESPONDENCE CONTROL TICKET

EDO

Date Printed: Feb 13, 2001 16:17

PAPER NUMBER: LTR-01-0107 **LOGGING DATE:** 02/13/2001
ACTION OFFICE: EDO ✓

AUTHOR: Carl Tommaso
AFFILIATION:
ADDRESSEE: CHRM Richard Meserve
SUBJECT: Requests the appointment of an interventional cardiologist to the Advisory Committee on the Medical Uses of Isotopes

ACTION: Appropriate
DISTRIBUTION: Chrm, Comrs

LETTER DATE: 02/08/2001
ACKNOWLEDGED: No
SPECIAL HANDLING: OCM #5372

NOTES:
FILE LOCATION: ADAMS
DATE DUE: **DATE SIGNED:**



The Society for Cardiac Angiography & Interventions

9111 Old Georgetown Road, Bethesda MD USA 20814-1699
 (800) 992-7224 Fax (301) 581-3408 e-mail: info@scai.org <http://www.scai.org>

Officers

Carl L. Tommaso, M.D., FSCAI
 President

Joseph D. Babb, M.D., FSCAI
 President-Elect

Ted. E. Feldman, M.D., FSCAI
 Secretary

Rita M. Watson, M.D., FSCAI
 Treasurer

Jeffrey J. Popma, M.D., FSCAI
 Immediate Past President

Trustees

J. Adolfo Cosentino, M.D., FSCAI

Michael J. Cowley, M.D., FSCAI

G. Neil Cumpston, M.D., FSCAI

Gregory J. Dehmer, M.D., FSCAI

Ted. E. Feldman, M.D., FSCAI

John McB. Hodgson, M.D., FSCAI

Alice K. Jacobs, M.D., FSCAI

Bonnie H. Weiner, M.D., FSCAI

Trustee for Life

William C. Sheldon, M.D., FSCAI

2001 Annual
 Scientific Sessions

Westin Galleria, Houston TX
 May 16-19, 2001

Albert E. Raizner, M.D., FSCAI
 Chairman

Earl F. Beard, M.D., FSCAI
 Co-Chairman

Neal S. Kleiman, M.D., FSCAI
 Co-Chairman

February 8, 2001

The Honorable Richard A. Meserve, Chairman
 United States Nuclear Regulatory Commission
 One White Flint North
 11555 Rockville Pike
 Rockville, MD 20852-2738

Dear Chairman Meserve:

In a December 20, 1999 letter, Dr. Arthur Garson, then President of the American College of Cardiology (ACC) wrote to you asking for the appointment of an interventional cardiologist on the Advisory Committee on the Medical Uses of Isotopes (ACMUI). A copy of his letter is attached.

The Society for Cardiac Angiography and Interventions (SCA&I) is a 2000 member organization of interventional cardiologists. We are closely allied with the ACC and have supported their efforts to gain access to the ACMUI. With the approval and proliferation of intravascular radiation, we believe that patients' best interests would be maintained by involvement of interventional cardiologists at each level of regulation and decision-making involving this procedure. We also believe that current iterations of intravascular radiation are first generation tools and significant evolution of this technology will occur.

As I am sure that you are aware, on November 3, 2000 the Food and Drug Administration approved the Novoste Beta-Cath™ System and the Checkmate™ System, intravascular radiation procedures to treat in-stent restenosis. The problem of restenosis is the largest complication of percutaneous coronary intervention since its inception. With the availability of intravascular radiation, there is now a therapeutic modality to attack this problem.

Therefore, in conjunction with the ACC we are asking that you consider the appointment of an interventional cardiologist to the ACMUI. We realize that Manuel Cerqueira, M.D., F.A.C.C. is the cardiology community's representative to the ACMUI; however, he is a recognized expert in nuclear cardiology and board certified in nuclear medicine. The expertise of an interventional cardiologist is different and would be an important addition to the ACMUI particularly in this time of the proliferation and evolution of a new technology.

February 8, 2001
The Honorable Richard A. Meserve, Chairman
United States Nuclear Regulatory Commission
Page Two

I hope that you will consider our request on behalf of the SCA&I, and the patients undergoing intravascular radiation.

Sincerely,

A handwritten signature in black ink, appearing to read "Carl L. Tommaso". The signature is fluid and cursive, with a small flourish at the end.

Carl L. Tommaso, M.D., F.S.C.A.I.
President, Society for Cardiac Angiography and Interventions

Attachment

cc: Commissioner Nils J. Diaz
Commissioner Greta Joy Dicus
Commissioner Edward McGaffigan, Jr.
Commissioner Jeffrey S. Merrifield
Donald A. Cool, Ph.D.
Catherine Haney
George A. Beller, M.D., F.A.C.C.
Manuel Cerqueira, M.D., F.A.C.C.
Warren K. Laskey, M.D., F.A.C.C.
George W. Vetovec, M.D., F.A.C.C.
Lawrence J. Laslett, M.D., F.A.C.C.



The Society for Cardiac Angiography & Interventions

9111 Old Georgetown Road, Bethesda MD USA 20814-1699
(800) 992-7224 Fax (301) 581-3408 e-mail: info@scai.org <http://www.scai.org>

Officers

Carl L. Tommaso, M.D., FSCAI
President

Joseph D. Babb, M.D., FSCAI
President-Elect

Ted. E. Feldman, M.D., FSCAI
Secretary

Rita M. Watson, M.D., FSCAI
Treasurer

Jeffrey J. Popma, M.D., FSCAI
Immediate Past President

Trustees

J. Adolfo Cosentino, M.D., FSCAI

Michael J. Cowley, M.D., FSCAI

G. Neil Cumpston, M.D., FSCAI

Gregory J. Dehmer, M.D., FSCAI

Ted. E. Feldman, M.D., FSCAI

John McB. Hodgson, M.D., FSCAI

Alice K. Jacobs, M.D., FSCAI

Bonnie H. Weiner, M.D., FSCAI

Trustee for Life

William C. Sheldon, M.D., FSCAI

2001 Annual Scientific Sessions

Westin Galleria, Houston TX
May 16-19, 2001

Albert E. Raizner, M.D., FSCAI
Chairman

Earl F. Beard, M.D., FSCAI
Co-Chairman

Neal S. Kleiman, M.D., FSCAI
Co-Chairman

February 8, 2001

The Honorable Richard A. Meserve, Chairman
United States Nuclear Regulatory Commission
One White Flint North
11555 Rockville Pike
Rockville, MD 20852-2738

Dear Chairman Meserve:

In a December 20, 1999 letter, Dr. Arthur Garson, then President of the American College of Cardiology (ACC) wrote to you asking for the appointment of an interventional cardiologist on the Advisory Committee on the Medical Uses of Isotopes (ACMUI). A copy of his letter is attached.

The Society for Cardiac Angiography and Interventions (SCA&I) is a 2000 member organization of interventional cardiologists. We are closely allied with the ACC and have supported their efforts to gain access to the ACMUI. With the approval and proliferation of intravascular radiation, we believe that patients' best interests would be maintained by involvement of interventional cardiologists at each level of regulation and decision-making involving this procedure. We also believe that current iterations of intravascular radiation are first generation tools and significant evolution of this technology will occur.

As I am sure that you are aware, on November 3, 2000 the Food and Drug Administration approved the Novoste Beta-Cath™ System and the Checkmate™ System, intravascular radiation procedures to treat in-stent restenosis. The problem of restenosis is the largest complication of percutaneous coronary intervention since its inception. With the availability of intravascular radiation, there is now a therapeutic modality to attack this problem.

Therefore, in conjunction with the ACC we are asking that you consider the appointment of an interventional cardiologist to the ACMUI. We realize that Manuel Cerqueira, M.D., F.A.C.C. is the cardiology community's representative to the ACMUI; however, he is a recognized expert in nuclear cardiology and board certified in nuclear medicine. The expertise of an interventional cardiologist is different and would be an important addition to the ACMUI particularly in this time of the proliferation and evolution of a new technology.

February 8, 2001
The Honorable Richard A. Meserve, Chairman
United States Nuclear Regulatory Commission
Page Two

I hope that you will consider our request on behalf of the SCA&I, and the patients undergoing intravascular radiation.

Sincerely,

A handwritten signature in black ink, appearing to read "Carl L. Tommaso". The signature is fluid and cursive, with a small flourish at the end.

Carl L. Tommaso, M.D., F.S.C.A.I.
President, Society for Cardiac Angiography and Interventions

Attachment

cc: Commissioner Nils J. Diaz
Commissioner Greta Joy Dicus
Commissioner Edward McGaffigan, Jr.
Commissioner Jeffrey S. Merrifield
Donald A. Cool, Ph.D.
Catherine Haney
George A. Beller, M.D., F.A.C.C.
Manuel Cerqueira, M.D., F.A.C.C.
Warren K. Laskey, M.D., F.A.C.C.
George W. Vetrovec, M.D., F.A.C.C.
Lawrence J. Laslett, M.D., F.A.C.C.



669

CHAIRMAN'S OFFICE ROUTE SLIP

TO:	NAME	INITIALS	TO:	NAME	INITIALS
	CHAIRMAN MESERVE ^{not} _{copy}			BARBARA GABRIEL	
	DENNIS RATHBUN			FRANCES MAREK	12/27
	GLENN TRACY			TERRY AGNEU	12/27
	BOB McOSKER				
	MARIAN ZOBLER				
	RICKIE BEALL				
	KAREN HENDERSON				
1	PATRICIA HOLAHAN	PH			
2	KEITH McCONNELL	km		MATERIALS ASSISTANTS	
	ALAN LEVIN			REACTORS ASSISTANTS	
	TERENCE CHAN			ALL ASSISTANTS	

REMARKS

FILE	SEE ME	NOTE & RETURN
------	--------	---------------

FROM (NAME)

FILE LOCATION:

✓ ACMUI

AMERICAN
COLLEGE of
CARDIOLOGY



Heart House
9111 Old Georgetown Road
Bethesda, MD 20814-1699
USA

301-897-5400
800-253-4636
Fax: 301-897-9745
<http://www.acc.org>

669

December 20, 1999

President

Arthur Garson, Jr., MD, MPH

President-Elect

George A. Beller, MD

Immediate Past President

Spencer B. King, III, MD

Vice President

Douglas P. Zipes, MD

Secretary

Nicholas T. Kouchoukos, MD

Assistant Secretary

W. Douglas Weaver, MD

Treasurer

Ben D. McCallister, MD

Assistant Treasurer

Michael D. Freed, MD

Chair, Board of Governors

L. Samuel Wann, MD

Trustees

Joseph S. Alpert, MD

Morton F. Arnsdorf, MD

George A. Beller, MD

Robert O. Bonow, MD

Melvin D. Cheitlin, MD

Michael H. Crawford, MD

Pamela S. Douglas, MD

Bernard W. D. Fong, MD

Michael D. Freed, MD

W. Bruce Fye, MD, MA

Arthur Garson, Jr., MD, MPH

Bernard J. Gersh, MB, ChB, DPhil

Raymond J. Gibbons, MD

Thomas P. Graham, Jr., MD

Sharon A. Hunt, MD

Spencer B. King, III, MD

Nicholas T. Kouchoukos, MD

Costas T. Lambrew, MD

Richard P. Lewis, MD

Marian C. Limacher, MD

Ben D. McCallister, MD

Joseph V. Messer, MD

Steven E. Nissen, MD

Michael A. Nocero, Jr., MD

Richard A. Poppo, MD

Robert Roberts, MD

George W. Vetovec, MD

L. Samuel Wann, MD

W. Douglas Weaver, MD

Michael J. Wolk, MD

Douglas P. Zipes, MD

Executive Vice President

Christine W. McEntee

The Honorable Richard A. Meserve, Chairman
United States Nuclear Regulatory Commission
One White Flint North
11555 Rockville Pike
Rockville, MD 20852-2738

Dear Chairman Meserve:

The American College of Cardiology (ACC), a medical society that represents 25,000 cardiovascular specialists, has been an active participant in the revision process of 10 CFR Part 35, "Medical Use of Byproduct Material." We believe that the proposed changes will maintain safety, decrease the regulatory burden and increase public confidence in the regulation of radiation.

The cardiology community has a special interest in the process not only with respect to the use of diagnostic applications such as myocardial perfusion imaging, but also in the evolving field of intravascular radiation for restenosis prevention (intravascular brachytherapy). We believe that this modality has the potential to overcome the biggest problem associated with interventional cardiology procedures: tissue proliferation. As the attached table (Clinical Trials Using Intravascular Brachytherapy for the Inhibition of Restenosis) demonstrates, intravascular radiation for restenosis prevention can be performed in many different ways. We appreciate the fact that the Nuclear Regulatory Commission (NRC) and Part 35 Writing Group have recognized the emerging nature of intravascular radiation for restenosis prevention and acknowledged these changing circumstances in the draft final rule version of 10 CFR, Part 35.1000. Following adoption of a standard protocol, the NRC will address regulatory treatment of intravascular radiation for restenosis prevention.

Over the years, the ACC has been pleased to nominate cardiologists to serve on the Advisory Committee on the Medical Uses of Isotopes (ACMUI). That representation has allowed the cardiology community to provide input into issues related to nuclear cardiology. The ACMUI has a broad composition that represents all the stakeholders in the medical use of byproduct materials. Dr. Manuel Cerqueira, the cardiology community's representative to the ACMUI, has been named to chair that panel. He is a recognized expert in nuclear cardiology and board certified in nuclear medicine. As chair, he will see that all viewpoints are represented fairly.

Dr. Cerqueira does not practice interventional cardiology or have expertise in the emerging technology of intravascular radiation for restenosis prevention. No one presently serving on the ACMUI has either the clinical and technical knowledge or experience sufficient to provide expertise on intravascular radiation. Given the significance of this emerging modality, the ACC believes it is appropriate for an interventional cardiologist to sit on the ACMUI.

An interventional cardiologist with expertise in intravascular radiation for restenosis prevention will provide the committee with the unique perspective required to understand the complicated issues involved in the clinical management of patients in the cardiac catheterization

12/22...To EDO for Appropriate Action...Copy to: Chairman, Comrs,
SECY/RAS...99-1084

laboratory where the studies will be performed. The addition of a representative from the interventional cardiology community would assure that the committee receive expert information from practitioners in the field. The cardiology community believes that the addition of an interventional cardiologist is critical to guaranteeing the safety of patients and users.

The cardiology community looks forward to a continuing dialogue with the NRC and the ACMUI on issues related to the medical uses of byproduct material in cardiology procedures. Addition of an interventional cardiologist to the ACMUI would assure that the advisory panel could provide the commissioners the most relevant information on new developments related to intravascular radiation for restenosis prevention.

Thank you for considering the views of the more than 25,000 ACC members.

Sincerely,



Arthur Garson, Jr., M.D., M.P.H., F.A.C.C.
President

Attachment

cc: Commissioner Nils J. Diaz
Commissioner Greta Joy Dicus
Commissioner Edward McGaffigan, Jr.
Commissioner Jeffrey S. Merrifield
Donald A. Cool, Ph.D.
Catherine Haney
George A. Beller, M.D., F.A.C.C.
Manuel Cerqueira, M.D., F.A.C.C.
Warren K. Laskey, M.D., F.A.C.C.
George W. Vetovec, M.D., F.A.C.C.
Lawrence J. Laslett, M.D., F.A.C.C.

1

**CLINICAL TRIALS USING INTRAVASCULAR BRACHYTHERAPY
FOR THE INHIBITION OF RESTENOSIS**

Study Name	Principal Investigator	Type of Trial	Trial Design	No. of Patients	Vascular Bed	Lesion Type	Treatment	Isotope	Type of Radiation	Dose or Activity	Delivery Platform	Delivery Method	Centered Source	Results and Status
Venezuela	Condado, et al	Feasibility	Open Label	21	Coronary	De novo	PTCA	¹⁹² Ir	Gamma	20-25 Gy (actual dose 19-55)	Catheter	Hand	Non-Centered	Completed. Clinical and angiographic follow-up to 24 months demonstrated safety and low late loss. Aneurysm noted in two.
SCRIPPS	Teirstein, et al	Feasibility, Efficacy	Randomized, Controlled	55	Coronary	Restenosis	PTCA and Stent	¹⁹² Ir	Gamma	3-30 Gy to media by IVUS	Catheter	Hand	Non-Centered	Completed. Significant reduction of restenosis (54% vs 17%) in the irradiated group.
Swiss I	Verni, et al	Phase I	Open Label	15	Coronary	De novo	PTCA	⁹⁰ Y	Beta	18 Gy to lumen surface	Catheter	Afterloader	Centered	Completed. Demonstrated feasibility and safety, but not efficacy (restenosis=40%).
BERT	King, et al	Phase I	Open Label	23	Coronary	De novo	PTCA	⁹⁰ Sr/Y	Beta	12, 14, 16 Gy to 2 mm from source.	Catheter	Hydraulic device	Non-Centered	Completed. Demonstrated feasibility and safety. Restenosis 15%. Late loss index of 4%.
BERT Canada	Bonan, et al	Phase I	Open Label	30	Coronary	De novo	PTCA	⁹⁰ Sr/Y	Beta	12, 14, 16 Gy to 2 mm from source.	Catheter	Hydraulic device	Non-Centered	Completed. Demonstrated feasibility and safety. Restenosis rate 10%. Negative late loss.
BERT European	Serruys, et al	Phase I	Open Label	30	Coronary	De novo	PTCA	⁹⁰ Sr/Y	Beta	12, 14, 16 Gy to 2 mm from source.	Catheter	Hydraulic device	Non-Centered	Enrollment completed. Data expected Summer, 1998.
PREVENT	Rauzner, et al	Phase I	Randomized, Controlled	84	Coronary	De novo or Restenosis	PTCA, Stent	³² P	Beta	0, 16, 20, 24 Gy to 1.0 mm into artery wall.	Catheter	Afterloader	Centered	Enrollment completed. Data expected Fall 1998.
WRIST	Waksman, et al	Phase II	Randomized, Controlled	100	Coronary	In-stent restenosis	PTCA, Stent	¹⁹² Ir	Gamma	15 Gy to 2.0 mm from source	Catheter	Hand	Non-Centered	Enrollment completed.
WRIST SVG	Waksman, et al	Phase II	Randomized, Controlled	120	Coronary	In-stent restenosis in saphenous vein grafts	PTCA, Stent	¹⁹² Ir	Gamma	15 Gy to 2.4 mm from source	Catheter	Hand	Non-Centered	Enrollment started December 1997

**CLINICAL TRIALS USING INTRAVASCULAR BRACHYTHERAPY
FOR THE INHIBITION OF RESTENOSIS**

Study Name	Principle Investigator	Type of Trial	Trial Design	No. of Patients	Vascular Bed	Lesion Type	Treatment	Isotope	Type of Radiation	Dose or Activity	Delivery Platform	Delivery Method	Centered Source	Results and Status
WRIST LONG	Waksman, et al	Phase II	Randomized, Controlled	120	Coronary	In-stent restenosis in long (36-88 mm) lesions.	PTCA, Stent	¹⁹² Ir	Gamma	15 Gy to 2.0 mm	Catheter	Hand	Non-Centered	Enrollment started January 1998
BETACATH	Kuntz, et al	Phase II	Randomized Control	1100	Coronary	De novo	PTCA, Provisional Stent	⁹⁰ Sr/Y	Beta	14, 18 Gy to 2 mm from source	Catheter	Hydraulic device	Non-Centered	Enrollment started July 1997
Swiss II	Verni, et al	Phase I	Open Label	160	Coronary	De novo	PTCA	⁹⁰ Y	Beta	9, 18, 32 Gy to Surface	Catheter	Afterloader	Centered	Enrollment started September 1997
GAMMA I	Leon, et al	Phase II	Randomized, Controlled	250	Coronary	In-stent restenosis	PTCA, Stent	¹⁹² Ir	Gamma	8 - 32 to media by IVUS	Catheter	Hand	Non-Centered	Enrollment started December 1997
CURE	Weinberger, et al	Feasibility and Safety	Open Label	60	Coronary	De novo or restenosis	PTCA, Stent	¹⁸⁸ Re	Beta	20 to balloon surface	Catheter	Liquid filled balloon	Centered	Enrollment started October 1997
ARREST	Waksman, et al	Phase II	Randomized, Controlled	700	Coronary	De novo	PTCA and provisional stenting	¹⁹² Ir	Gamma	8 - 35 to media by IVUS	Catheter	Afterloader	Centered	Enrollment started Spring, 1998
INHIBIT	Waksman, et al	Phase II	Randomized, Controlled	200	Coronary	In-stent restenosis	PTCA, Stent	³² P	Beta	20 to 1.0 mm into wall	Catheter	Afterloader	Centered	Enrollment anticipated June 1998.
IRIS IA	Fischell, et al	Phase I	Open label	32	Coronary	De novo, restenosis	Radioactive stent (PalmaZ-Schatz stent)	³² P	Beta	Low activity (0.5 to 1.0 µCi)	Stent	Catheter	Centered	Completed. Excellent feasibility and safety. Angiographic restenosis =31%
IRIS IB	Moses, et al	Phase I	Open label	25	Coronary	De novo, restenosis	Radioactive stent (PalmaZ-Schatz stent)	³² P	Beta	Activity 0.7 to 1.5 µCi	Stent	Catheter	Centered	Completed. Excellent feasibility and safety. Restenosis data available Summer, 1998
Heidelberg	Hehrli, et al	Phase I	Open label	15	Coronary	Restenosis	Radioactive stent (PalmaZ-Schatz stent)	³² P	Beta	Activity 3.0 µCi	Stent	Catheter	Centered	Enrollment completed. No major adverse events at four months.
Milan	Colombo	Phase I	Open label	?	Coronary	De novo, restenosis	Radioactive stent (PalmaZ-Schatz stent)	³² P	Beta	Activity 6.0 and 8.0 µCi	Stent	Catheter	Centered	Enrollment started January 1998.



**CLINICAL TRIALS USING INTRAVASCULAR BRACHYTHERAPY
FOR THE INHIBITION OF RESTENOSIS**

Study Name	Principle Investigator	Type of Trial	Trial Design	No. of Patients	Vascular Bed	Lesion Type	Treatment	Isotope	Type of Radiation	Dose or Activity	Delivery Platform	Delivery Method	Centered Source	Results and Status
Isostent	Fischell, et al	Phase I	Open label	30	Coronary	De novo, restenosis	Radioactive stent (BX stent)	³² P	Beta	Activity 0.7 to 1.5 μCi	Stent	Catheter	Centered	Enrollment started March 1998.
German	Liermann, et al	Feasibility and efficacy	Open label	25	Superficial femoral artery	De novo	PTA and stent	¹⁹² Ir	Gamma	12 Gy	Catheter	Afterloader	Non-Centered	Completed. Five-year follow-up shows 80% patency. No adverse radiation effects.
PARIS I	Waksman, et al	Phase I	Open label	30	Superficial femoral artery	De novo	PTA	¹⁹² Ir	Gamma	14 Gy	Catheter	Afterloader	Centered	Completed. Demonstrated feasibility and safety.
PARIS II	Waksman, et al	Phase II	Randomized controlled	300	Superficial femoral artery	De novo	PTA	¹⁹² Ir	Gamma	14 Gy	Catheter	Afterloader	Centered	Enrollment started June 1998.
Washington Hospital Center	Waksman, et al	Phase I	Open label	11	AV dialysis shunt	De novo, restenosis	PTA	¹⁹² Ir	Gamma	14 Gy	Catheter	Afterloader	Non-Centered	13 lesions. 40% patency at 44 weeks.
New York Hospital Center	Nori, et al	Phase I	Open label	10	AV dialysis shunt	De novo, or restenosis	PTA	Orthovoltage		8.12 Gy	External	External beam	Non-Centered	10 patients. 70% patency at 6 months.



**The Society for
Cardiac Angiography
& Interventions**

9111 Old Georgetown Road
Bethesda, MD 20814-1699



**The Honorable Richard A. Meserve, Chairman
United States Nuclear Regulatory Commission
One White Flint North
11555 Rockville Pike
Rockville, MD 20852-2738**

20852-2738 13

